Recent blog posts
PTK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTGDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTGDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTGDR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PRCD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PRCD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRCD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PRAME Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PRAME Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRAME sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PPARGC1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PPARGC1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARGC1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PPARD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PPARD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PNMA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PNMA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PNMA3 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PNMA3 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLAUR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →